vs

Side-by-side financial comparison of loanDepot, Inc. (LDI) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $310.3M, roughly 1.0× loanDepot, Inc.). loanDepot, Inc. runs the higher net margin — -7.2% vs -18.2%, a 11.0% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 20.5%). MADRIGAL PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-133.8M vs $-648.0M).

LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

LDI vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.0× larger
MDGL
$321.1M
$310.3M
LDI
Growing faster (revenue YoY)
MDGL
MDGL
+190.3% gap
MDGL
210.8%
20.5%
LDI
Higher net margin
LDI
LDI
11.0% more per $
LDI
-7.2%
-18.2%
MDGL
More free cash flow
MDGL
MDGL
$514.1M more FCF
MDGL
$-133.8M
$-648.0M
LDI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LDI
LDI
MDGL
MDGL
Revenue
$310.3M
$321.1M
Net Profit
$-22.5M
$-58.6M
Gross Margin
Operating Margin
-10.3%
-18.6%
Net Margin
-7.2%
-18.2%
Revenue YoY
20.5%
210.8%
Net Profit YoY
32.4%
1.4%
EPS (diluted)
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LDI
LDI
MDGL
MDGL
Q4 25
$310.3M
$321.1M
Q3 25
$323.3M
$287.3M
Q2 25
$282.5M
$212.8M
Q1 25
$273.6M
$137.3M
Q4 24
$257.5M
$103.3M
Q3 24
$314.6M
$62.2M
Q2 24
$265.4M
Q1 24
$222.8M
$0
Net Profit
LDI
LDI
MDGL
MDGL
Q4 25
$-22.5M
$-58.6M
Q3 25
$-4.9M
$-114.2M
Q2 25
$-13.4M
$-42.3M
Q1 25
$-21.9M
$-73.2M
Q4 24
$-33.2M
$-59.4M
Q3 24
$1.4M
$-107.0M
Q2 24
$-32.2M
Q1 24
$-34.3M
$-147.5M
Gross Margin
LDI
LDI
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
LDI
LDI
MDGL
MDGL
Q4 25
-10.3%
-18.6%
Q3 25
-3.2%
-39.7%
Q2 25
-11.4%
-22.2%
Q1 25
-16.8%
-57.8%
Q4 24
-32.7%
-64.8%
Q3 24
1.1%
-187.1%
Q2 24
-29.1%
Q1 24
-38.2%
Net Margin
LDI
LDI
MDGL
MDGL
Q4 25
-7.2%
-18.2%
Q3 25
-1.5%
-39.8%
Q2 25
-4.7%
-19.9%
Q1 25
-8.0%
-53.4%
Q4 24
-12.9%
-57.5%
Q3 24
0.4%
-172.0%
Q2 24
-12.1%
Q1 24
-15.4%
EPS (diluted)
LDI
LDI
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-5.08
Q2 25
$-1.90
Q1 25
$-3.32
Q4 24
$-2.50
Q3 24
$0.01
$-4.92
Q2 24
$-0.18
Q1 24
$-0.19
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LDI
LDI
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$337.2M
$198.7M
Total DebtLower is stronger
$2.1B
$339.9M
Stockholders' EquityBook value
$386.0M
$602.7M
Total Assets
$6.9B
$1.3B
Debt / EquityLower = less leverage
5.44×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LDI
LDI
MDGL
MDGL
Q4 25
$337.2M
$198.7M
Q3 25
$459.2M
$295.7M
Q2 25
$408.6M
$186.2M
Q1 25
$371.5M
$183.6M
Q4 24
$421.6M
$100.0M
Q3 24
$483.0M
$232.7M
Q2 24
$533.2M
Q1 24
$603.7M
$622.5M
Total Debt
LDI
LDI
MDGL
MDGL
Q4 25
$2.1B
$339.9M
Q3 25
$2.1B
$339.8M
Q2 25
$2.1B
$118.4M
Q1 25
$2.0B
$118.0M
Q4 24
$2.0B
$117.6M
Q3 24
$2.0B
$117.1M
Q2 24
$2.0B
Q1 24
$2.3B
$116.1M
Stockholders' Equity
LDI
LDI
MDGL
MDGL
Q4 25
$386.0M
$602.7M
Q3 25
$433.3M
$625.7M
Q2 25
$439.1M
$696.0M
Q1 25
$469.3M
$710.6M
Q4 24
$506.6M
$754.4M
Q3 24
$592.0M
$777.2M
Q2 24
$578.9M
Q1 24
$637.3M
$850.8M
Total Assets
LDI
LDI
MDGL
MDGL
Q4 25
$6.9B
$1.3B
Q3 25
$6.2B
$1.4B
Q2 25
$6.2B
$1.0B
Q1 25
$6.4B
$996.6M
Q4 24
$6.3B
$1.0B
Q3 24
$6.4B
$1.1B
Q2 24
$5.9B
Q1 24
$6.2B
$1.1B
Debt / Equity
LDI
LDI
MDGL
MDGL
Q4 25
5.44×
0.56×
Q3 25
4.83×
0.54×
Q2 25
4.70×
0.17×
Q1 25
4.30×
0.17×
Q4 24
4.00×
0.16×
Q3 24
3.31×
0.15×
Q2 24
3.41×
Q1 24
3.63×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LDI
LDI
MDGL
MDGL
Operating Cash FlowLast quarter
$-638.7M
$-133.5M
Free Cash FlowOCF − Capex
$-648.0M
$-133.8M
FCF MarginFCF / Revenue
-208.9%
-41.7%
Capex IntensityCapex / Revenue
3.0%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-734.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LDI
LDI
MDGL
MDGL
Q4 25
$-638.7M
$-133.5M
Q3 25
$43.4M
$79.8M
Q2 25
$67.6M
$-47.1M
Q1 25
$-179.9M
$-88.9M
Q4 24
$47.7M
$-104.5M
Q3 24
$-349.2M
$-67.0M
Q2 24
$-278.3M
Q1 24
$-278.5M
$-149.2M
Free Cash Flow
LDI
LDI
MDGL
MDGL
Q4 25
$-648.0M
$-133.8M
Q3 25
$38.7M
$79.0M
Q2 25
$61.4M
Q1 25
$-186.7M
Q4 24
$40.8M
$-104.7M
Q3 24
$-356.4M
$-67.8M
Q2 24
$-285.7M
Q1 24
$-283.3M
$-149.5M
FCF Margin
LDI
LDI
MDGL
MDGL
Q4 25
-208.9%
-41.7%
Q3 25
12.0%
27.5%
Q2 25
21.7%
Q1 25
-68.2%
Q4 24
15.8%
-101.3%
Q3 24
-113.3%
-109.0%
Q2 24
-107.7%
Q1 24
-127.2%
Capex Intensity
LDI
LDI
MDGL
MDGL
Q4 25
3.0%
0.1%
Q3 25
1.5%
0.3%
Q2 25
2.2%
0.0%
Q1 25
2.5%
0.0%
Q4 24
2.7%
0.2%
Q3 24
2.3%
1.3%
Q2 24
2.8%
Q1 24
2.1%
Cash Conversion
LDI
LDI
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-255.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LDI
LDI

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons